HealthCare21 Communications Ltd, part of the Lucid Group family. HC21 is a strategic medical communications agency that supports pharmaceutical companies active in specialty therapeutic areas through the development of highly relevant, technology-rich educational programmes and tools associated with long-term progressive conditions. Medical Education Grants (MEG) is a group within HC21 that collaborates with experts and independent entities on the development of valuable, clinically relevant and practical digital materials and CME through educational grants to advance medical practice, patient management and engagement. We answer your needs with a bespoke, flexible, personal and highly engaged service. Our integrated team is quick to plan, anticipate and respond. Our combination of strong scientific understanding and content development with technical know-how enables us to deliver high-quality, creative, educational projects that have a practical, tangible impact that embraces digital technology. Our specialty therapeutic area experience includes: Cardio-metabolism; Haemato-oncology; Hepatology; Infectious diseases/vaccines; Neurology; Ophthalmology; Paediatrics/neonatology; Radiology; Rare/orphan diseases; Rheumatology/inflammation/immunology; Transplantation; Urology Key activities: Ad boards * Advocacy development * CME * Congress reporting * Competitor intelligence * Customer insights * eLearning * Experiential learning * International product planning * KOL mapping/activities * LCM * Market access planning * Market development * Medical education * Meetings * Patient compliance * Patient education * Policy maker initiatives * Practice-based preceptorships * Quantitative/qualitative research * Social networking for patients * Strategic product positioning * Stakeholder priorities * Symposia * Value dossiers * Virtual preceptorships * Social media * Strategic pub planning * Real-world data * Steering groups *